Mirum Pharmaceuticals is striving to bring transformative medicines who have rare cholestastic liver conditions.  In keeping with their mission they have instituted a a Phase 3 study called MARCH to evaluate the safety and efficacy of maralixibat in pediatric patients with PFIC. Eligible patients in this clinical study may help provide new insights into PFIC and could lead to the first approved drug therapy.  For full details please visit https://pfictrial.com/